Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Anna Pluzanska"'
Autor:
Alain Ravaud, Istvan Bodrogi, Agnieszka Jagiełło-Gruszfeld, Sergio Bracarda, Piotr Koralewski, Bernard Escudier, Bohuslav Melichar, Vera Gorbunova, Christine Chevreau, Marek Filipek, Anna Pluzanska, Cezary Szczylik, Emilio Bajetta, Jacques-Olivier Bay, Nicola Moore
Publikováno v:
The Lancet. 370:2103-2111
Summary Background Vascular endothelial growth factor (VEGF) inhibition is a valid therapeutic approach in renal cell carcinoma. Therefore, an investigation of the combination treatment of the humanised anti-VEGF monoclonal antibody bevacizumab with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71f20b5f7238492312a6e80c3fcd8754
https://doi.org/10.1016/s0140-6736(07)61904-7
https://doi.org/10.1016/s0140-6736(07)61904-7
Autor:
Johan Vansteenkiste, Janusz Milanowski, Anna Pluzanska, Terezie Janaskova, Flavio De Rosa, Aleksandra Szczesna, Georgy M. Manikhas, E. Kaukel, Piotr Serwatowski, Rodryg Ramlau, Miloš Pešek, Jaromír Roubec, Ulrich Gatzemeier, Joachim von Pawel, Hanna Karnicka-Mlodkowski, János Strausz
Publikováno v:
Journal of Clinical Oncology. 25:1545-1552
Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase, with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of chemotherapy. This phase III, randomized, double-blind, place
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cce5b7afab9a77efddc233d733ae834b
https://doi.org/10.1200/jco.2005.05.1474
https://doi.org/10.1200/jco.2005.05.1474
Autor:
Joachim von Pawel, Giorgio V. Scagliotti, Pamela Rennie, Joan H. Schiller, Rafael Rosell, Abderrahim Fandi, Roy S. Herbst, Giuseppe Giaccone, Vincent A. Miller, Steven D. Averbuch, Ulrich Gatzemeier, Christian Manegold, John Grous, David H. Johnson, Ronald B. Natale, Anna Pluzanska, Judith S. Ochs, Michael K. Wolf
Publikováno v:
Journal of Clinical Oncology. 22:777-784
Purpose The purpose of this study was to determine whether the addition of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE) to standard first-line gemcitabine and cisplatin provide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdb440f88637631af780b474bc1d3e1f
https://doi.org/10.1200/jco.2004.08.001
https://doi.org/10.1200/jco.2004.08.001
Autor:
Maurizio Voi, Susan Marlin, Susan Dent, Lesley Seymour, David Lebwohl, Kathleen I. Pritchard, Laura Pearce, Anna Pluzanska, Dongsheng Tu, Janet Dancey, Tadeusz Pienkowski, A. Garin, Mary MacNeil, Karen A. Gelmon, Vera Gorbunova, Leonard M. Reyno, Jacek Jassem, Barbara Walley
Publikováno v:
Journal of Clinical Oncology. 22:269-276
Purpose N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine (DPPE; tesmilifene) is a novel agent that augments chemotherapy cytotoxicity in vitro and in vivo. A phase II trial combining DPPE and doxorubicin (DOX) in metastatic breast carcinoma showed i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6da541c9eee3370eb0cf0ad859b4fa8d
https://doi.org/10.1200/jco.2003.04.075
https://doi.org/10.1200/jco.2003.04.075
Autor:
Carsten Rose, O Vtoraya, R Thomas, F. Ben Ayed, JJ Caicedo, M Gershanovich, H. A. Chaudri-Ross, R. Lang, Anna Pluzanska, N Davidson, Scott A. Johnson, H Gervasio, G Manikhas, S Burdette-Radoux
Publikováno v:
European Journal of Cancer. 39:2318-2327
It was previously shown that letrozole (Femara) was significantly more potent than anastrozole (Arimidex) in inhibiting aromatase activity in vitro and in inhibiting total body aromatisation in patients with breast cancer. The objective of this study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8dd6cb9f868cb2b9f94abe6825ac5e3b
https://doi.org/10.1016/s0959-8049(03)00630-0
https://doi.org/10.1016/s0959-8049(03)00630-0
Autor:
Michael Millward, Chandra P. Belani, Anna Pluzanska, José Rodrigues Pereira, Vera Gorbounova, Frank V. Fossella, Aleksandra Szczesna, K. Mattson, E. Kaukel, Panagiotis Fidias, Joachim von Pawel, Rodryg Ramlau
Publikováno v:
Journal of Clinical Oncology. 21:3016-3024
Purpose: To investigate whether docetaxel plus platinum regimens improve survival and affect quality of life (QoL) in advanced non–small-cell lung cancer (NSCLC) compared with vinorelbine plus cisplatin as first-line chemotherapy. Patients and Meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb2d3d8a4f78a8380c4c9ce543c6af68
https://doi.org/10.1200/jco.2003.12.046
https://doi.org/10.1200/jco.2003.12.046
Autor:
Liisa Hakamies-Blomqvist, Jonas Bergh, Nils-Olof Bengtsson, Henning T. Mouridsen, Johanna Sjöström, Anna Pluzanska, L. Tennvall, Minna-Liisa Luoma, Vahur Valvere, S. Ottoson, Per-Uno Malmström, Carl Blomqvist
Publikováno v:
European Journal of Cancer. 39:1370-1376
The purpose of the study was to investigate whether baseline quality of life (QoL) and changes in QoL scores from baseline are prognostic for time to progression (TTP) and/or overall survival (OS) in patients with advanced breast cancer receiving doc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df713075837a42190f19ab74495bb131
https://doi.org/10.1016/s0959-8049(02)00775-x
https://doi.org/10.1016/s0959-8049(02)00775-x
Autor:
Hennig Mouridsen, Ragnar Hultborn, Liisa Hakamies-Blomqvist, Per-Uno Malmström, Carl Blomqvist, Johan Ahlgren, Björn Ostenstaad, Ingvil Mjaaland, Nils-Olof Bengtsson, Anna Pluzanska, Minna Liisa Luoma, Gudjon Baldursson, Erik Wist, Johanna Sjöström, Vahur Valvere
Publikováno v:
Acta Oncologica. 41:44-49
The aim of this study was to study the relationship between physician-assessed quality of life parameters, i.e., toxicity and physical performance, and patients' self-reports of their quality of life (QoL). QoL was assessed at baseline and before eac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcb1b7959ccface916db87426ea26716
https://doi.org/10.1080/028418602317314055
https://doi.org/10.1080/028418602317314055
Autor:
Henning T. Mouridsen, J. Arnold Verbeek, Yan Sun, Eeva Salminen, H. A. Chaudri-Ross, Fritz Jänicke, Dominique Becquart, Justus Apffelstaedt, Beatrix Staffler, Anna Pluzanska, Magdolna Dank, Robert S. Smith, Ramon Perez-Carrion, Margaret Dugan, Mikhail Gershanovich, Alain Monnier, Mercedes Lassus, Poonamalle P. Bapsy, Harm Sleeboom, Corrado Boni, Raymond Snyder
Publikováno v:
Journal of Clinical Oncology. 19:2596-2606
PURPOSE: To compare the efficacy and tolerability of tamoxifen with that of letrozole, an oral aromatase inhibitor, with tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer. PATIENTS AND METHODS: Nine hundred seven pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c1db3f2ace9ebe08ee91f8d4c3a0473
https://doi.org/10.1200/jco.2001.19.10.2596
https://doi.org/10.1200/jco.2001.19.10.2596
Autor:
Maciej Krzakowski, Anna Pluzanska, Ulf Aasebø, Kazimierz Roszkowski, Annamaria Parisi, Alexander Peter Smith, Jocelyne Berille, Eugeni Saigi, Ngoc Pham Tran, Robert Olivares
Publikováno v:
Lung Cancer. 27:145-157
This was an open-label randomized Phase III study of 207 patients with either unresectable or metastatic non-small cell lung cancer (NSCLC) who were treated with docetaxel plus best supportive care (BSC) or best supportive care alone. Patients in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfb0f4c6f906ac092a3391413858bae5
https://doi.org/10.1016/s0169-5002(00)00094-5
https://doi.org/10.1016/s0169-5002(00)00094-5